While fecal microbiota transplants are recommended for multiple recurrent Clostridioides difficile infection, their use in clinical practice is hindered by a lack of regulation and understanding of the underlying ecological dynamics. This article covers major challenges for the treatment in transitioning from bench to bedside, from the scientific, clinical and regulatory perspectives (Part 6).

It has been 10 years since GMFH was launched with the aim of disseminating the latest gut microbiome research to the lay public, healthcare professionals and scientists alike. In this article, members of the GMFH board of experts share their pick of the most significant advances in the field, outlining their clinical impact and implications for further research.

Clostridioides difficile infection is a common cause of diarrhea in both the hospital and community settings, with C. difficile recurrence one of the most challenging outcomes to address. This article focuses on the factors that predict long-term complications of C. difficile infection and what can be done in clinical practice to minimize them (Part 5).

November, Clostridioides difficile infection awareness month

11 Nov 2022

by Konstantina Zafeiropoulou

Just one month before friends and families gather around the Christmas table, November is here to bring awareness around Clostridioides difficile infection, and the importance of microbiota-derived treatments. With this post, all of us in GMFH aim to highlight the importance of protecting ourselves and families and stopping the spread of this potentially deadly infection.